Response rates of taxane rechallenge in metastatic breast cancer patients, previously treated with adjuvant taxanes.

被引：1
|
作者：
Oguz, Arzu
Babacan, Taner
Dizdar, Omer
Kucukoztas, Nadire
Rahatli, Samed
Keskin, Gul Sema Yildiran
Altundag, Ozden
Altundag, Kadri
机构：
[1] Baskent Univ, Dept Med Oncol, TR-06490 Ankara, Turkey
[2] Hacettepe Univ, Inst Oncol, Dept Med Oncol, Ankara, Turkey
[3] Baskent Univ Hosp, Ankara, Turkey
[4] Baskent Univ, Sch Med, TR-06490 Ankara, Turkey
[5] Baskent Univ, Fac Med, TR-06490 Ankara, Turkey
[6] Hacettepe Univ, Inst Canc, Dept Med Oncol, Ankara, Turkey
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.1073
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1073
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Response rates of taxane rechallenge in metastatic breast cancer patients previously treated with adjuvant taxanes
    Kucukoztas, Nadire
    Oguz, Arzu
    Rahatli, Samed
    Altundag, Ozden
    Altundag, Kadri
    JOURNAL OF BUON, 2016, 21 (05): : 1076 - 1081
  • [2] Gemcitabine in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Evaluation of response toxicity
    Lerzo, GL
    Temperley, G
    Rosales, C
    Campos, C
    Lezcano, A
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S74 - S74
  • [3] Efficacy of taxane rechallenge in early metastatic relapse of HER2-negative breast cancer patients previously treated with taxane
    Vasseur, A.
    Carton, M.
    Guiu, S.
    Augereau, P.
    Uwer, L.
    Reynier, M. A. Mouret
    Levy, C.
    Eymard, J- C.
    Goncalves, A.
    Robert, M.
    Rouge, T. De La Motte
    Bachelot, T.
    Petit, T.
    Debled, M.
    Grinda, T.
    Desmoulins, I.
    Vanlemmens, L.
    Dalenc, F.
    Simon, G.
    Cabel, L.
    ANNALS OF ONCOLOGY, 2021, 32 : S501 - S502
  • [4] Phase II study of vinorelbine (NVB) and UFT in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes.
    Anton, A
    Puertolas, T
    Ramos, M
    Barnadas, A
    Florian, J
    Grande, R
    Ribelles, N
    Lomas, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 64S - 64S
  • [5] Phase II clinical trial of ixabepilone in metastatic breast cancer (MBC) patients previously untreated with taxanes.
    Denduluri, N.
    Lee, J. J.
    Walshe, J. M.
    Yang, S. X.
    Vatas, U.
    Chow, C. K.
    Steinberg, S. M.
    Cox, M. C.
    Low, J. A.
    Swain, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 40S - 40S
  • [6] Safety and efficacy of low-dose metronomic cyclophosphamide plus vinorelbine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
    Kudo, Shun
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane
    Ahn, JH
    Kim, SB
    Kim, TW
    Ahn, SH
    Kim, SM
    Park, JM
    Lee, JS
    Kang, YK
    Kim, WK
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2004, 19 (04) : 547 - 553
  • [8] Phase II study with the combination of capecitabine (C) and vinorelbine (V) in metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes.
    Estevez, LG
    Batista, N
    Sánchez-Rovira, P
    Velasco, A
    Domine, M
    Lobo, F
    Oramas, J
    Cruz, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 63S - 63S
  • [9] Bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
    Schmid, P
    Schippinger, V
    Kiewe, P
    Lange, W
    Preiss, J
    Niederle, N
    Brossart, P
    Freier, W
    Van de Velde, H
    Possinger, K
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S68 - S69
  • [10] Evolving Approaches to Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes
    Murphy, Conleth G.
    Seidman, Andrew D.
    CLINICAL BREAST CANCER, 2009, 9 : S58 - S65
12345